Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7168986 | 0.98 | KIF11 (0.52) | TBXA2RALDH1A1KIF11MAPK1MAPT | |
| SCHEMBL6304679 | 0.87 | NPC1 (0.47) | TBXA2RALDH1A1KIF11MAPK1HDAC3 | |
| SCHEMBL17164962 | 0.86 | LMNA (0.51) | ALDH1A1KIF11MAPK1HDAC3HDAC4 | |
| SCHEMBL4211757 | 0.85 | KIF11 (0.57) | ALDH1A1KIF11MAPK1MAPTRXFP1 | |
| SCHEMBL30625928 | 0.81 | KIF11 (0.56) | KIF11MAPTKCNN4DUT | |
| SCHEMBL29601869 | 0.81 | KIF11 (0.45) | ALDH1A1KIF11HDAC3HDAC1HDAC2 | |
| SCHEMBL14286703 | 0.80 | KIF11 (0.55) | ALDH1A1KIF11MAPTHDAC6KCNN4 | |
| SCHEMBL913501 | 0.80 | KIF11 (0.55) | ALDH1A1KIF11MAPTHDAC6KCNN4 | |
| SCHEMBL12264133 | 0.79 | KIF11 (0.68) | ALDH1A1KIF11MAPTKCNN4DUT | |
| SCHEMBL3684180 | 0.78 | KIF11 (0.57) | ALDH1A1KIF11MAPTKCNN4DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741044-B2 | Libraries of oligomers labeled with different tags | OXFORD GENE TECHNOLOGY IP LIMITED | 2010-06-22 | — | — | US | disclosed |
| US-20090029866-A1 | Libraries of oligomers labeled with different tags | OXFORD GENE TECHNOLOGY IP LIMITED | 2009-01-29 | — | — | US | disclosed |
| US-7399846-B2 | Libraries of oligomers labeled with different tags | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2008-07-15 | — | — | US | disclosed |
| US-20050003408-A1 | Libraries of oligomers labeled with different tags | ISIS INNOVATION LIMITED (GB) | 2005-01-06 | — | — | US | disclosed |
| US-6780981-B1 | MAKING A SET OF LABELLED COMPOUNDS BY THE USE OF PARTICULATE SUPPORT, COMPRISES DIVIDING THE SUPPORT INTO LOTS, PERFORMING A DIFFERENT CHEMICAL REACTION ON EACH LOT OF THE SUPPORT | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2004-08-24 | — | — | US | disclosed |
| EP-1428810-A2 | Libraries of oligomers labelled with different tags | Oxford Gene Technology IP Limited (GB) | 2004-06-16 | — | — | EP | disclosed |
| US-RE38416-E1 | NUCLEOTIDE BASES COMPRISING PYRAZOLO(3,4-D)PYRIMIDINES USED FOR MEDICAL DIAGNOSIS, THERAPY, HYBRIDIZATION, ANTISENSE AGENTS OR REPORTER MOLECULES | EPOCH BIOSCIENCES, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1068216-B1 | LIBRARIES OF OLIGOMERS LABELLED WITH DIFFERENT TAGS | ISIS INNOVATION (GB) | 2003-12-10 | — | — | EP | disclosed |
| US-5912340-A | FORMING STABLE HYBRID WITH DNA, RNA | EPOCH PHARMACEUTICALS, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| US-5849482-A | Crosslinking oligonucleotides | EPOCH PHARMACEUTICALS, INC. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5824796-A | MEDICAL DIAGNOSIS WITH TARGET DNA OR RNA FOR ENZYME INHIBITORS | EPOCH PHARMACEUTICALS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| EP-0842186-A1 | CROSS-LINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997012896-A1 | SELECTIVE BINDING COMPLEMENTARY OLIGONUCLEOTIDES | EPOCH PHARMACEUTICALS, INC. (US) | 1997-04-10 | — | — | WO | disclosed |
| US-5618938-A | Process for preparing stereo isomers of neurokinin receptor antagonists | SANOFI (FR) | 1997-04-08 | — | — | US | disclosed |
| WO-1996040711-A1 | CROSS-LINKING OLIGONUCLEOTIDES | MICROPROBE CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0661979-A4 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION. | MICROPROBE CORP (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0661979-A1 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION | MICROPROBE CORPORATION (US) | 1995-07-12 | — | — | EP | disclosed |
| US-5317020-A | Neurokinin receiver antagonist as antiinflammatory agents | SANOFI (FR) | 1994-05-31 | — | — | US | disclosed |
| WO-1993003736-A1 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION | MICROPROBE CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| WO-1990003370-A1 | DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE | MICROPROBE CORPORATION (US) | 1990-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029866-A1 | Libraries of oligomers labeled with different tags | FBL, HNRNPL, MTREX | TBXA2R 3182/4885ALDH1A1 4746/4885KIF11 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.